Intellia Therapeutics (NTLA) Preferred Stock Liabilities (2015 - 2016)
Intellia Therapeutics' (NTLA) quarterly Preferred Stock Liabilities came in at $88.6 million in Q1 2016, little changed on a QoQ basis from $88.6 million in Q4 2015.
Intellia Therapeutics (NTLA) Preferred Stock Liabilities (2015 - 2016) Analysis & Trends
Intellia Therapeutics (NTLA) has 2 years of Preferred Stock Liabilities data on file, last reported at $88.6 million in Q1 2016.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $88.6 million in Q1 2016; TTM through Mar 2016 was $88.6 million, a N/A change from a year earlier, with the FY2015 full-year figure at $88.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2016 stood at $88.6 million, roughly flat from $88.6 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for NTLA reached as high as $88.6 million in Q1 2016 and fell as low as $88.6 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Intellia Therapeutics | 1.32 Bn | 1.32 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 88.62 Mn |
| Dec 31, 2015 | 88.56 Mn |